Literature DB >> 6631715

Effect of hydralazine on tension and membrane potential in the rat caudal artery.

K Hermsmeyer, A Trapani, P W Abel, M Worcel.   

Abstract

To determine whether the vasodilator, hydralazine (HYD), produces hyperpolarization of vascular muscle cells, we measured the effect of HYD on membrane potential and contractile responses to phenylephrine and K+. HYD (1 microM) caused a 4 mV hyperpolarization of phenylephrine-depolarized arteries (compared with controls without HYD), which could possibly account for up to three-fourths of the 39% decrease in tension measured. K+-contracted vessels were also 34% relaxed by 1 microM HYD without an effect on membrane potential. In addition, HYD further relaxed phenylephrine-stimulated vessels previously relaxed by D-600, suggesting that Ca++ channel blockade may not be an important mechanism of vasodilation for HYD. The evidence suggests that a nonmembrane action of HYD on arterial muscle probably multiplies the relaxant effect of membrane potential hyperpolarization. Both mechanisms would attenuate the effects of adrenergic stimulation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6631715

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery.

Authors:  D C Ellershaw; A M Gurney
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.

Authors:  T Münzel; S Kurz; S Rajagopalan; M Thoenes; W R Berrington; J A Thompson; B A Freeman; D G Harrison
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

3.  Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine.

Authors:  A M Gurney; M Allam
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.